Citadel Advisors
BBH icon

Citadel Advisors’s VanEck Biotech ETF BBH Stock Holding History

Citadel Advisors’s Portfolio BBH Stock Details BBH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$526K Buy
+2,800
New +$540K ﹤0.01% 9178

Other funds holding BBH

Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
MIM
Miller Investment Management West Conshohocken, Pennsylvania $1.01B AUM 13.96% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
CCA
Conservest Capital Advisors Wynnewood, Pennsylvania $1.1B AUM 16.5% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
BFG
Bleakley Financial Group Fairfield, New Jersey $6.39B AUM 26.33% 1-Year Est. Return

Citadel Advisors's BBH Position: Q1 2026 in Review

Citadel Advisors opened a new position in VanEck Biotech ETF (BBH) in Q1 2026: 9,514 shares worth $1.79M. The stake represents ﹤0.01% of the portfolio and ranks #6318 among its holdings. This is a return to the name: Citadel Advisors previously reported a position in BBH as recently as Q3 2025.

Citadel Advisors first reported a position in BBH in Q2 2014 and has held it in 34 quarters since. The position peaked at $6.05M in Q1 2019. 112 funds tracked by Wall St. Rank hold BBH as of Q1 2026.

  • Citadel Advisors held 9,514 shares of VanEck Biotech ETF worth $1.79M as of Q1 2026.
  • VanEck Biotech ETF was a new Citadel Advisors position in Q1 2026.
  • VanEck Biotech ETF made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #6318 holding.
  • Citadel Advisors first reported a position in VanEck Biotech ETF in Q2 2014 and has held it in 34 quarters since.
  • Citadel Advisors's VanEck Biotech ETF position peaked at $6.05M in Q1 2019.
  • 112 funds tracked by Wall St. Rank held VanEck Biotech ETF as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.